REM Sleep Behavior Disorder

Abstract

REM sleep behavior disorder (RBD) is a parasomnia in which the muscle paralysis that normally accompanies rapid-eye-movement sleep fails, so that the sleeper physically acts out the content of vivid, often violent dreams — punching, kicking, shouting, or leaping from the bed. Its interest for cognitive neuroscience is twofold. First, it is a natural lesion of a specific brainstem circuit: the loss of REM atonia exposes the motor output of the dreaming brain, turning the hidden imagery of REM sleep into observable behaviour. Second, idiopathic RBD is recognised as the strongest known early marker of neurodegeneration: most people who develop it go on to develop Parkinson's disease or a related synucleinopathy, because the same ascending alpha-synuclein pathology damages the REM-atonia circuits of the brainstem first. RBD opens the longest prodromal window medicine has found into diseases of the ageing brain.

Keywords: REM sleep behavior disorder, REM atonia, synucleinopathy

Most parasomnias are curiosities — sleepwalking, night terrors, teeth-grinding — troubling to the sleeper but of limited theoretical weight. REM sleep behavior disorder is the exception, and the reason is a discovery made only after the disorder itself was described. When Carlos Schenck and Mark Mahowald first characterised RBD in 1986, they had found a clean behavioural syndrome: elderly men, for the most part, who lost the normal paralysis of dreaming sleep and enacted their dreams, sometimes injuring themselves or a bed partner (Schenck et al., 1986). What transformed the finding from a sleep-clinic entity into a subject of intense neuroscientific interest was the follow-up: tracked over years, most of these patients developed a neurodegenerative disease (Schenck & Mahowald, 2002).

That trajectory is what makes RBD valuable well beyond the sleep laboratory. It is at once a window on the machinery of REM sleep — showing what the dreaming brain would do if its motor brake were released — and the earliest reliable sign that a slow neurodegenerative process has begun, often a decade or more before the tremor or the memory loss that would otherwise announce it. The account below moves from what the disorder is, through the brainstem circuit whose failure produces it, to the phenoconversion to Parkinson's disease and dementia that dominates its long-term course, and finally to how it is diagnosed and where its study is now heading. The recurring theme is that a single sleep sign, correctly read, can reveal the state of the whole brain.

Figure 1

The REM-Atonia Brake and Its Failure

What REM Sleep Behavior Disorder Is

REM sleep behavior disorder is a parasomnia — a disorder of abnormal behaviour arising from sleep — defined by the loss of the normal skeletal-muscle paralysis of REM sleep and the consequent enactment of dreams (Schenck et al., 1986). In Medical Subject Headings it is filed as a REM sleep parasomnia and cross-listed under both nervous-system and mental disorders, reflecting its dual identity as a neurological sign and a sleep complaint. The behaviours range from small hand movements and sleep-talking to violent punching, kicking, and jumping, and because they are enactments of dream content they are typically defensive or combative: the dreamer is fighting off an attacker or an animal, and the bed partner is often the one injured.

Two features separate RBD from the more familiar parasomnias of deep sleep, such as sleepwalking. First, it arises out of REM rather than non-REM sleep, so it occurs in the second half of the night when REM predominates, and the enacted content is a coherent, recalled dream rather than the confused, amnesic arousal of a sleepwalker. Second, on waking the person is immediately alert and can usually report the dream, and that dream matches the observed movements (Olson, Boeve, & Silber, 2000). The classic case series of ninety-three patients established the demographic signature that still holds: RBD is strongly male-predominant and emerges characteristically after age fifty, with a mean onset around sixty (Olson et al., 2000).

The disorder comes in two forms whose distinction is the whole of its clinical importance. Symptomatic or secondary RBD accompanies an identifiable cause — narcolepsy, a brainstem lesion, or certain antidepressant medications. Idiopathic or isolated RBD arises with no apparent cause, and it is this form that carries the profound prognostic weight: what looks like an isolated sleep problem is, in most cases, the first clinical manifestation of a neurodegenerative disease still years from diagnosis (Iranzo et al., 2006). The term idiopathic is therefore increasingly regarded as provisional, a label for a disease process not yet visible elsewhere rather than for the genuine absence of one.

The Loss of REM Atonia

To understand RBD one must first understand why the dreaming body is normally still. REM sleep is a paradoxical state: the cortex is highly active, generating vivid dreams, yet the skeletal muscles are profoundly paralysed, held in an active atonia that is a defining feature of the stage rather than a mere absence of movement. This paralysis is imposed by a specific brainstem circuit. Glutamatergic neurons in the sublaterodorsal nucleus (the pontine region corresponding to the sublaterodorsal or subcoeruleus area) are active during REM sleep and drive inhibitory — GABAergic and glycinergic — neurons in the ventromedial medulla, which in turn hyperpolarise the spinal motor neurons, silencing the muscles while the dream unfolds (Boeve et al., 2007).

RBD is the failure of this circuit. When the sublaterodorsal nucleus or its inhibitory projections are damaged, the REM generator continues to produce dreams and to activate the motor cortex, but the brake on the final motor pathway is released, so the motor commands of the dream reach the muscles and the dream is acted out (Boeve, 2010). The animal work that first mapped this circuit is decisive: lesions of the equivalent pontine region in the cat abolish REM atonia and produce oneiric behaviour — the cat appears to enact hunting or grooming during REM sleep — a near-exact model of the human disorder, confirming that RBD is a lesion of the atonia-generating system rather than an excess of dreaming (Boeve et al., 2007).

The location of this circuit is the key to everything that follows. The relevant nuclei lie in the pons and medulla, low in the brainstem, and this is precisely where the alpha-synuclein pathology of the synucleinopathies is thought to begin before ascending to the midbrain and cortex. On the influential staging scheme proposed by Braak and colleagues, sporadic Parkinson's pathology follows an orderly caudo-rostral progression: it appears first in the lower brainstem and olfactory structures and only later ascends to the substantia nigra, whose degeneration produces the classic motor signs, and later still to the cortex (Braak et al., 2003). Because the atonia-generating nuclei sit squarely in those early, low-brainstem stages, they are damaged before the nigra, so RBD is the behavioural readout of early, low-brainstem synuclein pathology — which is why it can precede every other sign of the disease (Boeve et al., 2007).

RBD as a Prodrome of Neurodegeneration

The observation that reorganised the field came from long-term follow-up. Schenck and Mahowald's sixteen-year review reported that a striking majority of the men originally diagnosed with idiopathic RBD had gone on to develop a parkinsonian disorder or dementia, establishing for the first time that the sleep disorder was, in most cases, a harbinger of neurodegeneration (Schenck & Mahowald, 2002). What had looked like an isolated parasomnia was in fact the leading edge of a slow disease.

Prospective studies confirmed and quantified the link. Iranzo and colleagues followed a cohort of patients with idiopathic RBD and found that neurodegenerative disease — predominantly Parkinson's disease and dementia with Lewy bodies — emerged in the large majority over the ensuing years, cementing RBD's status as the most specific clinical prodrome of the synucleinopathies yet identified (Iranzo et al., 2006). The diseases RBD foreshadows share a common pathology — the aggregation of the protein alpha-synuclein — and are collectively the synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. RBD does not precede the other major cause of dementia, Alzheimer's disease, and this specificity is part of its diagnostic value: it points to a particular disease family, not to neurodegeneration in general.

The definitive estimate of the risk came from a large multicentre study pooling cohorts across the world. Following more than a thousand patients with idiopathic RBD, it found an overall phenoconversion rate of about 6% per year, rising to roughly three-quarters of patients converting within twelve years, with the eventual diagnosis split between a parkinsonism-first and a dementia-first presentation (Postuma et al., 2019). The same study identified markers that stratify the risk — abnormal motor testing, olfactory loss, mild cognitive impairment, and others — that bring forward the expected time of conversion. This slow, quantified trajectory is what makes RBD so valuable: it defines a population, identifiable years in advance, in whom a future disease is nearly certain, which is exactly the population that neuroprotective trials require.

The relationship also runs the other way. RBD is not only a herald of these diseases but a frequent feature of them once established: it is present in a large share of patients with diagnosed Parkinson's disease, where it is associated with longer disease duration, greater autonomic and cognitive involvement, and a more malignant phenotype overall (Sixel-Döring et al., 2011). The three diseases that idiopathic RBD foreshadows are set out in Table 1.

Diagnosis and Assessment

RBD cannot be diagnosed from the history alone, because dream-enactment behaviour has other causes — ordinary sleepwalking, the confusional arousals of sleep apnea, and nocturnal seizures among them — and distinguishing them requires seeing the sleep itself. The diagnosis therefore rests on video-polysomnography: an overnight recording of brain activity, eye movements, muscle tone, and behaviour, reviewed to establish two things together (St Louis et al., 2017). The first is the objective physiological signature, REM sleep without atonia (RSWA): abnormally preserved or elevated muscle tone during REM sleep, measured from the chin and limb electromyogram, which is the direct electrophysiological correlate of the failed atonia circuit. The second is the demonstration, on the synchronised video, of the abnormal behaviour arising specifically from REM sleep.

Both elements are required, and the reason is instructive. REM sleep without atonia can occasionally be seen without clinical dream enactment, and dream-enactment-like behaviour can arise from non-REM parasomnias or apnea; only the conjunction of the electromyographic sign with observed REM-related behaviour is diagnostic (St Louis et al., 2017). Quantifying RSWA is itself a technical undertaking, with validated scoring of tonic and phasic muscle activity against established cut-offs, because the amount of retained muscle tone is a graded rather than an all-or-none measure.

Alongside the laboratory study, screening questionnaires identify candidates for referral. The most widely used, the REM Sleep Behavior Disorder Screening Questionnaire, asks about the cardinal features — vivid dreams, aggressive or violent dream content, movements matching the dream, and injuries to self or bed partner — and a score above its cut-off flags the need for polysomnography. Screening matters increasingly because the diagnosis is no longer merely a matter of treating the nocturnal behaviour — important though that is, since injury is common and clonazepam and melatonin substantially reduce it (McCarter et al., 2013) — but of identifying, and then following, a person at very high risk of a future neurodegenerative disease (Fernandez-Arcos et al., 2016).

Worked Example

Because RBD's prognostic weight rests on a conversion rate, it is worth working through how an annual rate accumulates into a lifetime risk. Take the headline figure from the large multicentre cohort: an overall phenoconversion rate of about 6% per year (Postuma et al., 2019). The simplest way to project this forward is a constant-hazard model, in which each disease-free year carries the same independent chance of conversion. If the annual conversion probability is 6%, then the chance of remaining disease-free through any one year is:

1 − 0.06 = 0.94

Because each year is treated as independent, the probability of remaining disease-free across several years is that figure raised to the power of the number of years. Over five years:

disease-free = 0.94⁵ = 0.734, so converted = 1 − 0.734 = 26.6%

Over ten years the disease-free fraction falls further:

disease-free = 0.94¹⁰ = 0.539, so converted = 1 − 0.539 = 46.1%

So a constant 6% annual hazard implies that roughly a quarter of patients convert within five years and nearly half within ten — already a remarkable concentration of risk. Yet the empirical cohorts report still higher cumulative conversion, around three-quarters by twelve years (Postuma et al., 2019). The gap is itself informative: it tells us the hazard is not constant but rising, because the pathology is progressive and the accumulation of additional risk markers — hyposmia, subtle motor signs, cognitive change — steepens the curve as time passes. The constant-hazard arithmetic is therefore a floor, not an estimate: it shows that even the most conservative reading of the annual rate implies eventual conversion for the majority, and the true trajectory is faster. The demonstration below lets the annual rate and the follow-up period be varied to trace how the cumulative risk builds.

Discussion

RBD occupies an unusual position in the cognitive and brain sciences because it is simultaneously a basic-science probe and a clinical instrument of the first importance. As a probe, it is the cleanest natural demonstration that the vivid imagery of REM dreams is accompanied by genuine, patterned motor commands that are ordinarily blocked at the final common path. When the brake fails, the enacted behaviours are not random thrashing but organised, dream-congruent actions, which tells us the dreaming brain is running detailed motor programs in real time and that atonia is what keeps them from being executed (Boeve, 2010). Dreaming, on this evidence, is not a passive spectacle but an activity the body is fully prepared to carry out.

As a clinical instrument, RBD has reframed how neurodegenerative disease is conceived. Parkinson's disease and dementia with Lewy bodies were long defined by their motor and cognitive signs — that is, by the point at which substantial numbers of neurons had already been lost. RBD shifts the detectable onset years earlier, to a stage when the pathology is still confined to the brainstem, and in doing so it converts these diseases from conditions diagnosed at their motor climax into conditions with a long, identifiable prodrome (Postuma et al., 2019). This is the single most important consequence of the disorder's study, because a treatment that could slow or halt the underlying process would have to be given during exactly this window, before the losses that produce symptoms become irreversible.

The deeper lesson unites the two roles. A disorder of one small sleep-control circuit turns out to be a sensitive early readout of the state of the whole brain, because that circuit happens to lie in the path of a spreading pathology. It is a reminder that in a densely interconnected nervous system, the most informative sign is not always the most dramatic one, and that a symptom dismissed for decades as a mere sleep quirk can, once properly understood, offer the longest forewarning medicine has of a disease that will not otherwise declare itself for years (Hogl, Stefani, & Videnovic, 2018).

Current Directions

The dominant current effort is the search for biomarkers that predict when an individual with RBD will convert and to which disease, so that the prodromal window RBD defines can be used for neuroprotective trials. An international consensus has catalogued the candidates — dopaminergic imaging, olfactory testing, quantitative motor and cognitive measures, and emerging fluid and tissue markers of alpha-synuclein — and assessed how each performs at stratifying risk within the RBD population (Miglis et al., 2021). The goal is a predictive profile precise enough to enrol the right patients at the right time, since a trial of a disease-slowing therapy is only feasible in people whose conversion is both likely and reasonably dated.

A closely related development is the direct detection of the pathological protein itself. Seed-amplification assays that detect misfolded alpha-synuclein in cerebrospinal fluid and other tissues have shown that the great majority of people with idiopathic RBD already carry the molecular signature of a synucleinopathy, turning what was an inference from long-term follow-up into a contemporaneous biological fact (Miglis et al., 2021). Together with the recognition that isolated RBD is now best understood as prodromal synucleinopathy rather than a free-standing sleep disorder (Hogl et al., 2018), these advances are moving the field toward a future in which the disorder is not merely treated for its nocturnal danger but used as the entry point for the first genuinely early interventions against Parkinson's disease and related conditions.

Common Misconceptions

“RBD is just a form of sleepwalking.”

It is fundamentally different. Sleepwalking arises from deep non-REM sleep, involves confused and amnesic behaviour, and occurs early in the night; RBD arises from REM sleep, involves the enactment of a coherent, recalled dream, and occurs in the REM-rich second half of the night (Olson et al., 2000).

“Acting out dreams is harmless and not worth investigating.”

Two things make it worth investigating. The behaviours cause frequent injury to the sleeper and bed partner, and idiopathic RBD is the strongest known early sign of a future neurodegenerative disease, so its diagnosis carries major prognostic information (Postuma et al., 2019).

“A diagnosis of RBD means Parkinson's disease is certain and imminent.”

Neither. Conversion is common but not universal, and it unfolds slowly — at roughly 6% of patients per year, with a prodromal window often exceeding a decade — so a diagnosis signals substantially elevated long-term risk, not an immediate sentence (Postuma et al., 2019).

“RBD can be diagnosed from the symptoms without a sleep study.”

It cannot. Dream-enactment behaviour has several mimics, so the diagnosis requires video-polysomnography to demonstrate REM sleep without atonia together with the behaviour arising from REM sleep (St Louis et al., 2017).

Glossary

Alpha-synuclein.

A neuronal protein whose misfolding and aggregation define the synucleinopathies; its early accumulation in the lower brainstem is thought to produce RBD before other signs of disease appear.

Clonazepam.

A benzodiazepine long used as a first-line treatment for the nocturnal behaviours of RBD; it reduces the movements and injury risk but does not alter the underlying neurodegenerative risk.

Dementia with Lewy bodies.

A synucleinopathy marked by fluctuating cognition, visual hallucinations, and parkinsonism; the characteristic dementia-first outcome of RBD phenoconversion, in which RBD is a core diagnostic feature.

Dream enactment.

The physical acting-out of dream content during sleep; in RBD the enacted movements are congruent with the dream the person reports on waking.

Electromyogram (EMG).

The recording of muscle electrical activity; in the sleep laboratory the chin and limb EMG is the channel on which REM sleep without atonia is measured and scored.

Idiopathic (isolated) RBD.

RBD arising with no identifiable cause; now understood in most cases as prodromal synucleinopathy rather than a free-standing disorder.

Melatonin.

A hormone and its pharmaceutical form, increasingly used as a better-tolerated first-line treatment for RBD's nocturnal behaviours, often in place of or alongside clonazepam.

Multiple system atrophy.

A rapidly progressive synucleinopathy combining autonomic failure with parkinsonism or cerebellar signs; a less common but very strongly associated endpoint of RBD, in which RBD is near-universal.

Parasomnia.

A disorder of abnormal behaviour, movement, or experience arising from sleep or the transitions into and out of it; RBD is a parasomnia of REM sleep.

Phenoconversion.

The transition from the prodromal state (RBD alone) to a clinically diagnosable neurodegenerative disease such as Parkinson's disease or dementia with Lewy bodies.

Polysomnography.

The overnight recording of brain, eye, muscle, and cardiorespiratory activity used to stage sleep; video-polysomnography adds synchronised behavioural video and is required to diagnose RBD.

REM atonia.

The active, near-complete paralysis of skeletal muscle that normally accompanies REM sleep; its loss is the defining disturbance of RBD.

REM sleep without atonia (RSWA).

Abnormally preserved or elevated muscle tone during REM sleep on the electromyogram; the objective polysomnographic signature of RBD.

Sublaterodorsal nucleus.

The pontine brainstem region whose glutamatergic neurons drive the inhibitory circuit that imposes REM atonia; its damage releases the muscles and produces RBD.

Synucleinopathy.

A neurodegenerative disease characterised by alpha-synuclein aggregation — Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy — the disease family RBD foreshadows.

Video-polysomnography (vPSG).

Overnight polysomnography with synchronised behavioural video; the required diagnostic test for RBD, demonstrating REM sleep without atonia together with abnormal behaviour arising from REM sleep.

Key Researchers

Bradley F. Boeve

(living). Neurologist at the Mayo Clinic whose case series and pathophysiology reviews mapped the brainstem basis of RBD and its tight relationship to the synucleinopathies (Olson et al., 2000; Boeve et al., 2007). ORCID · Faculty page

Yves Dauvilliers

(living). Neurologist and sleep researcher at the University of Montpellier and lead author of the authoritative disease primer synthesising the clinical, mechanistic, and prognostic understanding of RBD (Dauvilliers et al., 2018). ORCID

Birgit Hogl

(living). Neurologist at the Medical University of Innsbruck whose work has advanced the recognition of RBD as prodromal synucleinopathy and the standardisation of its diagnosis (Hogl et al., 2018). ORCID

Alex Iranzo

(living). Neurologist at the Hospital Clinic de Barcelona whose prospective cohort provided some of the first firm evidence that idiopathic RBD is an early marker of Parkinson's disease and related disorders (Iranzo et al., 2006; Fernandez-Arcos et al., 2016). ORCID · Faculty page

Mark W. Mahowald

(1943–2020). Neurologist and long-time director of the Minnesota Regional Sleep Disorders Center who co-discovered RBD and helped establish the modern understanding of the parasomnias (Schenck et al., 1986). His foundational work defined the disorder that is now the leading prodromal marker of synucleinopathy. In Memoriam (AASM)

Ronald B. Postuma

(living). Neurologist at McGill University who led the large multicentre study quantifying the rate and predictors of phenoconversion in idiopathic RBD (Postuma et al., 2019). ORCID

Carlos H. Schenck

(living). Psychiatrist and sleep researcher at the University of Minnesota who, with Mark Mahowald, first described and named REM sleep behavior disorder in 1986 and later documented its progression to neurodegenerative disease (Schenck et al., 1986; Schenck & Mahowald, 2002). ORCID

Frequently Asked Questions

What is REM sleep behavior disorder?

REM sleep behavior disorder (RBD) is a sleep disorder in which the muscle paralysis that normally accompanies dreaming sleep fails, so the person physically acts out their dreams — punching, kicking, shouting, or leaping from bed. Because the movements enact dream content, they are often violent, and injuries to the sleeper or bed partner are common.

How is RBD different from sleepwalking?

Sleepwalking arises from deep non-REM sleep early in the night and involves confused, amnesic behaviour. RBD arises from REM sleep later in the night, and the person enacts a coherent dream they can usually recall on waking, with the movements matching the remembered dream.

Why does RBD happen?

During normal REM sleep a brainstem circuit actively paralyses the muscles while the brain dreams. In RBD this circuit — centred on a region of the pons called the sublaterodorsal nucleus — is damaged, so the motor commands of the dream are no longer blocked and reach the muscles, producing enactment.

Is RBD linked to Parkinson's disease?

Yes, strongly. Idiopathic RBD is the most reliable early warning sign of the synucleinopathies, a family of diseases that includes Parkinson's disease and dementia with Lewy bodies. Most people with idiopathic RBD eventually develop one of these conditions, often more than a decade later.

Does everyone with RBD develop a neurodegenerative disease?

Not everyone, but the majority do over time. Long-term studies find conversion at a rate of roughly 6% of patients per year, reaching about three-quarters of patients by twelve years of follow-up. The process is slow, so a diagnosis signals high long-term risk rather than imminent disease.

How is RBD diagnosed?

It requires an overnight sleep study with video — video-polysomnography — to show two things together: abnormally preserved muscle tone during REM sleep (called REM sleep without atonia) and the abnormal behaviour arising specifically from REM sleep. Symptoms alone cannot confirm it, because other conditions can mimic dream enactment.

Can RBD be treated?

The nocturnal behaviour can be managed. Melatonin and the drug clonazepam substantially reduce the movements and the risk of injury, and making the sleep environment safe is important. These treatments control the symptoms but do not alter the underlying risk of later neurodegenerative disease.

Why is RBD important to brain science?

It serves two roles. It is the clearest natural demonstration that the dreaming brain generates real motor commands normally blocked by paralysis, and it provides the longest known early window into Parkinson's disease and related disorders — the window in which a future treatment to slow those diseases would need to act.

References